Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Wingrove Theresa
 2. Date of Event Requiring Statement (Month/Day/Year)
12/09/2016		 3. Issuer Name and Ticker or Trading Symbol
IMMUNOGEN INC [IMGN]
(Last)
(First)
(Middle)
C/O IMMUNOGEN, INC., 830 WINTER STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP of Regulatory Affairs
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WALTHAM, MA 02451		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 01/18/2012(1) 01/18/2021 Common Stock 37,500 $ 9.85 D  
Stock Option (right to buy) 07/22/2012(2) 07/22/2021 Common Stock 20,000 $ 15.2 D  
Stock Option (right to buy) 07/20/2013(3) 07/20/2022 Common Stock 40,000 $ 15.83 D  
Stock Option (right to buy) 07/16/2014(4) 07/16/2023 Common Stock 40,000 $ 19.02 D  
Stock Option (right to buy) 07/17/2015(5) 07/17/2024 Common Stock 40,000 $ 10.79 D  
Stock Option (right to buy) 07/13/2016(6) 07/13/2025 Common Stock 48,000 $ 16.72 D  
Stock Option (right to buy) 06/01/2017(7) 06/01/2026 Common Stock 4,000 $ 5.75 D  
Stock Option (right to buy) 07/18/2017(8) 07/18/2026 Common Stock 50,000 $ 3.05 D  
Stock Option (right to buy) 09/30/2017(9) 09/30/2026 Common Stock 38,000 $ 2.68 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Wingrove Theresa
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM, MA 02451		       VP of Regulatory Affairs  

Signatures

/s/ Craig Barrows, attorney in fact 12/16/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) All options exercisable as of filing date.
(2) All options exercisable as of filing date.
(3) All options exercisable as of filing date.
(4) All options exercisable as of filing date.
(5) 26,667 options exercisable as of filing date and 13,333 shares exercisable commencing on July 17, 2017.
(6) 16,000 options exercisable as of filing date, 16,000 shares exercisable commencing on July 13, 2017, and 16,000 shares exercisable commencing on July 13, 2018.
(7) Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares commencing on June 1, 2018, and 1,333 shares commencing on June 1, 2019.
(8) Exercisable as to 16,667 shares commencing on July 18, 2017, 16,667 shares commencing on July 18, 2018, and 16,666 shares commencing on July 18, 2019.
(9) Exercisable as to 12,667 shares commencing on September 30, 2017, 12,667 shares commencing on September 30, 2018, and 12,666 shares commencing on September 30, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.